Nuvation Bio Inc. (NUVB) Stock Price & How to Invest

Nuvation Bio (NYSE: NUVB) is a San Francisco oncology company founded by David Hung, best known for previously building and selling Medivation. Its commercial anchor is IBTROZI (taletrectinib), a next-generation oral ROS1 tyrosine kinase inhibitor that received full FDA approval in June 2025 for locally advanced or metastatic ROS1-positive non-small cell lung cancer across lines of therapy. The drug is positioned against first-generation options like Pfizer's Xalkori and Roche's Rozlytrek and the newer Bristol Myers Squibb agent Augtyro, and it has been added as a preferred option in NCCN guidelines. Beyond IBTROZI, the pipeline includes safusidenib (a brain-penetrant IDH1 inhibitor), NUV-1511 (a drug-drug conjugate), and NUV-868 (a BET inhibitor).

The investment picture is a transition from cash-burning developer to revenue-generating commercial company. IBTROZI net U.S. product revenue was about $18.5 million in Q1 2026, up roughly 18% sequentially, with more than 600 patients started on the drug since launch. Nuvation has layered on ex-U.S. licensing deals (Eisai for Europe and other markets, Innovent in China where it sells as Dovbleron, and Nippon Kayaku in Japan) that bring upfront payments, milestones, and royalties. A large one-time Eisai upfront pushed reported Q1 2026 revenue to about $83 million and produced a rare quarterly profit, but the underlying recurring product sales are still modest and building.

IBTROZI targets a relatively small ROS1-positive niche, so peak sales are inherently capped and depend on diagnostic testing rates and competition from Roche's Rozlytrek and BMS's Augtyro. Reported profitability in Q1 2026 was flattered by a one-time Eisai upfront, and recurring product revenue is still small relative to a market capitalization around $1.7 billion. The company has issued equity (a 2026 shelf/offering) and could dilute further, and much of the pipeline beyond taletrectinib is early-stage with binary trial and regulatory outcomes. As a single-product commercial company, any launch stumble, pricing pressure, or safety signal would weigh heavily on the shares.

10 analysts publish price targets on NUVB, averaging $13.10 against a $6.64 price as of September 2026, or +97.3%. The published targets run from $7.00 to $21.00, a wide spread, and the ratings split 10 buy, 1 hold, 0 sell. Over the last six months there have been 3 raises and 1 cut among the published actions. A price target is what an analyst published on a date, not a prediction, and sell-side ratings skew positive across the whole market.

Read the full NUVB forecast and price target for the target table, the recent rating actions by firm, and how the consensus has shifted.

We give no verdict on Nuvation Bio Inc.. Both cases are real, which is why the question is contested at all, so here is the strongest version of each.

The case for buying. IBTROZI commercial ramp. The core driver is uptake of IBTROZI in ROS1-positive NSCLC, a targeted but real U.S. The most optimistic published target, $21.00, assumes this works close to its best case.

The case against. IBTROZI targets a relatively small ROS1-positive niche, so peak sales are inherently capped and depend on diagnostic testing rates and competition from Roche's Rozlytrek and BMS's Augtyro. The most pessimistic target, $7.00, is roughly what NUVB is worth if this bites instead.

Read the full bull and bear case on NUVB, including what would have to change to break either one. Walnut is not an investment adviser.

A simple financial snapshot. These are approximations and refresh quarterly; for current figures see Nuvation Bio Inc.'s investor relations page or your broker.

• Market cap: ~$1.7B
• Share price (mid-2026): ~$4.80
• Revenue (TTM): ~$130M (boosted by one-time license upfronts)
• IBTROZI product revenue (Q1 2026): ~$18.5M
• Cash and marketable securities: ~$534M
• Q1 2026 net income: ~$5.4M (aided by Eisai upfront)

Reported TTM revenue is inflated by large one-time collaboration upfronts, so the recurring product run-rate (roughly $74 million annualized and growing) is a more conservative gauge of the commercial base. With over $500 million in cash against a market capitalization near $1.7 billion, the balance sheet is well funded, and the valuation largely reflects expectations for future IBTROZI growth and royalty streams rather than current recurring sales.

Other names that sit close to NUVB: same theme, named as a direct competitor, or held beside it in the same funds. Each entry says which. Worth a look if you are thinking about diversification within a thesis rather than concentration on one ticker.

There are three common ways to get NUVB exposure. Buy shares (or fractional shares) directly at any major broker. Hold an ETF that includes it, which spreads the position across many companies. Or build it into a focused thematic portfolio, so NUVB sits alongside other stocks that express the same thesis.

Walnut takes the portfolio route. Describe a thesis where NUVB fits (for example “AI infrastructure” or “dividend-growth large-caps”) and the AI proposes 5 to 6 constituents with target weights. You review the plan and fund it through your own broker when you're ready.

New to this? Start with how to invest in stocks, see how to analyze a stock with AI, or compare the best AI stock analyzers.

Nuvation Bio has crossed from a clinical-stage bet into an early commercial oncology company, and the debate now is how large and fast IBTROZI sales scale against a well-funded field of ROS1 rivals.

Whether NUVB is worth buying today depends more on your time horizon and what you already hold than on any single call. We walk through valuation, what would have to go right, and the risks in is NUVB a buy or a sell?, and where the stock could go from here in the NUVB stock forecast.

For income investors, whether NUVB pays a dividend and how the payout looks is covered in does NUVB pay a dividend? And to weigh NUVB against a peer, read the full side-by-side comparisons: NUVB vs BMY and NUVB vs PFE.